Compare Stocks → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CRBP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBPCorbus Pharmaceuticals$42.99-1.7%$39.01$3.03▼$49.87$407.89M2.46210,574 shs92,122 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBPCorbus Pharmaceuticals-1.71%+10.88%+12.69%+94.09%+361.76%The A.I. story nobody is telling you (Read ASAP) (Ad)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRBPCorbus Pharmaceuticals3.8523 of 5 stars2.52.00.04.72.63.30.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBPCorbus Pharmaceuticals3.00Buy$53.0023.28% UpsideCurrent Analyst RatingsLatest CRBP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2024CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$58.00 ➝ $60.003/13/2024CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$51.00 ➝ $58.003/6/2024CRBPCorbus PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$4.00 ➝ $46.00(Data available from 5/11/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBPCorbus Pharmaceuticals$880K513.44N/AN/A($1.56) per share-27.56Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBPCorbus Pharmaceuticals-$44.60M-$10.37N/AN/AN/AN/A-920.31%-111.56%8/13/2024 (Estimated)Latest CRBP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/12/2024Q4 2023CRBPCorbus Pharmaceuticals-$2.36-$1.81+$0.55-$1.81N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBPCorbus PharmaceuticalsN/A0.740.74OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBPCorbus Pharmaceuticals64.64%Insider OwnershipCompanyInsider OwnershipCRBPCorbus Pharmaceuticals4.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCRBPCorbus Pharmaceuticals1910.51 million10.09 millionOptionableCRBP HeadlinesSourceHeadlineCorbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conferenceglobenewswire.com - May 9 at 8:00 AMCRBP Corbus Pharmaceuticals Holdings, Inc.seekingalpha.com - May 9 at 6:49 AMCorbus Pharmaceuticals (NASDAQ:CRBP) Price Target Raised to $60.00 at Oppenheimermarketbeat.com - May 8 at 1:09 PMCRBP Stock Earnings: Corbus Pharmaceuticals Beats EPS for Q1 2024investorplace.com - May 7 at 3:22 PMCorbus Pharmaceuticals to Participate in the BTIG Obesity Health Forumglobenewswire.com - May 1 at 8:00 AMCorbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meetingglobenewswire.com - April 24 at 4:05 PMNeutral On Corbus Pharmaceuticals' Financials And Clinical Progress In Oncologyseekingalpha.com - April 21 at 12:45 AM7 A-Rated Aggressive Biotech Stocks to Bet On in 2024finance.yahoo.com - April 20 at 9:43 AMThese 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?investorplace.com - April 19 at 2:30 PMHere's What Could Help Corbus Pharmaceuticals (CRBP) Maintain Its Recent Price Strengthmsn.com - April 16 at 1:09 PMCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Short Interest Updatemarketbeat.com - April 14 at 2:55 PMCorbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADCglobenewswire.com - April 2 at 8:00 AMCRBP Factor-Based Stock Analysisnasdaq.com - March 22 at 8:18 PMBuffett Can't Get Enough of This Stock, Plus Other Insider Buying247wallst.com - March 17 at 9:10 AMWhat Makes Corbus Pharmaceuticals (CRBP) a Good Fit for 'Trend Investing'zacks.com - March 15 at 9:51 AMCorbus Pharmaceuticals files for $300M mixed shelf offeringmsn.com - March 13 at 8:20 PMCorbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - March 12 at 1:05 PMCorbus Pharmaceuticals: Q4 Earnings Snapshotseattlepi.com - March 12 at 1:05 PMCorbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Updateglobenewswire.com - March 12 at 8:00 AMInsider Buying: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Major Shareholder Buys 250,000 Shares of Stockinsidertrades.com - March 12 at 4:34 AMCRBP Apr 2024 25.000 putfinance.yahoo.com - March 11 at 4:25 PMCRBP Mar 2024 45.000 putfinance.yahoo.com - March 11 at 6:24 AMCRBP Jun 2024 50.000 putfinance.yahoo.com - March 10 at 10:11 PMCRBP Jun 2024 50.000 callfinance.yahoo.com - March 10 at 10:11 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCorbus PharmaceuticalsNASDAQ:CRBPCorbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
